Literature DB >> 34376056

Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.

Sarah R Oikemus1, Edith L Pfister2, Ellen Sapp3, Kathryn O Chase2, Lori A Kennington2, Edward Hudgens1, Rachael Miller2, Lihua Julie Zhu1, Akanksh Chaudhary1, Eric O Mick4, Miguel Sena-Esteves5, Scot A Wolfe1,6, Marian DiFiglia3, Neil Aronin2,7, Michael H Brodsky1.   

Abstract

Huntington's disease (HD) is a devastating, autosomal dominant neurodegenerative disease caused by a trinucleotide repeat expansion in the huntingtin (HTT) gene. Inactivation of the mutant allele by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 based gene editing offers a possible therapeutic approach for this disease, but permanent disruption of normal HTT function might compromise adult neuronal function. Here, we use a novel HD mouse model to examine allele-specific editing of mutant HTT (mHTT), with a BAC97 transgene expressing mHTT and a YAC18 transgene expressing normal HTT. We achieve allele-specific inactivation of HTT by targeting a protein coding sequence containing a common, heterozygous single nucleotide polymorphism (SNP). The outcome is a marked and allele-selective reduction of mHTT protein in a mouse model of HD. Expression of a single CRISPR-Cas9 nuclease in neurons generated a high frequency of mutations in the targeted HD allele that included both small insertion/deletion (InDel) mutations and viral vector insertions. Thus, allele-specific targeting of InDel and insertion mutations to heterozygous coding region SNPs provides a feasible approach to inactivate autosomal dominant mutations that cause genetic disease.

Entities:  

Keywords:  Huntington's disease; gene editing; single nucleotide polymorphism

Mesh:

Substances:

Year:  2022        PMID: 34376056      PMCID: PMC8819514          DOI: 10.1089/hum.2020.323

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  51 in total

1.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

Review 2.  Development and applications of CRISPR-Cas9 for genome engineering.

Authors:  Patrick D Hsu; Eric S Lander; Feng Zhang
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

3.  Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.

Authors:  Mireia Garriga-Canut; Carmen Agustín-Pavón; Frank Herrmann; Aurora Sánchez; Mara Dierssen; Cristina Fillat; Mark Isalan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-10       Impact factor: 11.205

4.  A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Authors:  J G Hodgson; N Agopyan; C A Gutekunst; B R Leavitt; F LePiane; R Singaraja; D J Smith; N Bissada; K McCutcheon; J Nasir; L Jamot; X J Li; M E Stevens; E Rosemond; J C Roder; A G Phillips; E M Rubin; S M Hersch; M R Hayden
Journal:  Neuron       Date:  1999-05       Impact factor: 17.173

5.  Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque.

Authors:  K Tyler McCullough; Sanford L Boye; Diego Fajardo; Kaitlyn Calabro; James J Peterson; Christianne E Strang; Dibyendu Chakraborty; Sebastian Gloskowski; Scott Haskett; Steven Samuelsson; Haiyan Jiang; C Douglas Witherspoon; Paul D Gamlin; Morgan L Maeder; Shannon E Boye
Journal:  Hum Gene Ther       Date:  2018-12-20       Impact factor: 5.695

Review 6.  The delivery challenge: fulfilling the promise of therapeutic genome editing.

Authors:  Joost van Haasteren; Jie Li; Olivia J Scheideler; Niren Murthy; David V Schaffer
Journal:  Nat Biotechnol       Date:  2020-06-29       Impact factor: 54.908

7.  AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.

Authors:  J Miniarikova; V Zimmer; R Martier; C C Brouwers; C Pythoud; K Richetin; M Rey; J Lubelski; M M Evers; S J van Deventer; H Petry; N Déglon; P Konstantinova
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

8.  Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Yaoying Wu; Matthew P Gemberling; Matthew L Oliver; Matthew A Waller; Joel D Bohning; Jacqueline N Robinson-Hamm; Karen Bulaklak; Ruth M Castellanos Rivera; Joel H Collier; Aravind Asokan; Charles A Gersbach
Journal:  Nat Med       Date:  2019-02-18       Impact factor: 53.440

9.  A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells.

Authors:  Christopher A Vakulskas; Daniel P Dever; Garrett R Rettig; Rolf Turk; Ashley M Jacobi; Michael A Collingwood; Nicole M Bode; Matthew S McNeill; Shuqi Yan; Joab Camarena; Ciaran M Lee; So Hyun Park; Volker Wiebking; Rasmus O Bak; Natalia Gomez-Ospina; Mara Pavel-Dinu; Wenchao Sun; Gang Bao; Matthew H Porteus; Mark A Behlke
Journal:  Nat Med       Date:  2018-08-06       Impact factor: 53.440

10.  AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.

Authors:  Melvin M Evers; Jana Miniarikova; Stefan Juhas; Astrid Vallès; Bozena Bohuslavova; Jana Juhasova; Helena Kupcova Skalnikova; Petr Vodicka; Ivona Valekova; Cynthia Brouwers; Bas Blits; Jacek Lubelski; Hana Kovarova; Zdenka Ellederova; Sander J van Deventer; Harald Petry; Jan Motlik; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-06-25       Impact factor: 11.454

View more
  3 in total

1.  Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease.

Authors:  Jun Wan Shin; Aram Shin; Seri S Park; Jong-Min Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-04       Impact factor: 6.698

2.  Mutant allele knockout with novel CRISPR nuclease promotes myelopoiesis in ELANE neutropenia.

Authors:  Peter Sabo; Vahagn Makaryan; Yosef Dicken; Lital Povodovski; Liat Rockah; Tzlil Bar; Matan Gabay; Dalia Elinger; Ella Segal; Ora Haimov; Maya Antoshvili; Anat London Drori; Tanoya Poulsen; Asael Herman; Rafi Emmanuel; David C Dale
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-09       Impact factor: 5.849

3.  Targeted gene silencing in the nervous system with CRISPR-Cas13.

Authors:  Jackson E Powell; Colin K W Lim; Ramya Krishnan; Tristan X McCallister; Christian Saporito-Magriña; Maria A Zeballos; Garrett D McPheron; Thomas Gaj
Journal:  Sci Adv       Date:  2022-01-19       Impact factor: 14.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.